
doi: 10.1007/bf00558433
pmid: 378673
Ten patients with persistent ventricular arrhythmia were studied in a comparison of the antiarrhythmic efficacy of N-acetylprocainamide (NAPA) and procainamide (PA). Each patient performed three exercise tests for 40 min., on different days, with submaximal and fixed work loads. During the first exercise test no drug was administered. During the following two tests PA and NAPA, respectively, were administered by intravenous infusion. The electrocardiogram was continously recorded and was analyzed minute by minute. Blood samples for determination of plasma drug concentration were frequently collected. Exercise alone did not significantly change the incidence of arrhythmia. Both PA and NAPA showed a similar and significant antiarrhythmic effect. A blood pressure fall was seen in two patients after administration of each drug. No other adverse reaction was observed.
Adult, Male, Clinical Trials as Topic, Time Factors, Arrhythmias, Cardiac, Middle Aged, Procainamide, Electrocardiography, Injections, Intravenous, Humans, Female, Aged
Adult, Male, Clinical Trials as Topic, Time Factors, Arrhythmias, Cardiac, Middle Aged, Procainamide, Electrocardiography, Injections, Intravenous, Humans, Female, Aged
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 21 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
